{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:33:48Z","timestamp":1783467228652,"version":"3.55.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002997","name":"Dutch Kidney Foundation","doi-asserted-by":"publisher","award":["18OKG04"],"award-info":[{"award-number":["18OKG04"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,27]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The only treatment proven to be renoprotective in autosomal dominant polycystic kidney disease (ADPKD) is a vasopressin V2-receptor antagonist (V2RA). However, aquaresis-associated side effects limit tolerability. We investigated whether salt and\/or protein intake influences urine volume and related endpoints in V2RA-treated ADPKD patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this randomized, controlled, double-blind, crossover trial, ADPKD patients treated with maximally tolerated dose of a V2RA were included. While on a low salt and low protein diet, patients were given additional salt and protein to mimic regular intake, which was subsequently replaced by placebo in random order during four 2-week periods. Primary endpoint was change in 24-h urine volume. Secondary endpoints were change in quality of life, measured glomerular filtration rate (mGFR), blood pressure and copeptin level.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twelve patients (49\u00a0\u00b1\u00a08\u00a0years, 25.0% male) were included. Baseline salt and protein intake were 10.8\u00a0\u00b1\u00a01.3\u00a0g\/24-h and 1.2\u00a0\u00b1\u00a00.2\u00a0g\/kg\/24-h, respectively. During the low salt and low protein treatment periods, intake decreased to 5.8\u00a0\u00b1\u00a01.6\u00a0g\/24-h and 0.8\u00a0\u00b1\u00a00.1\u00a0g\/kg\/24-h, respectively. Baseline 24-h urine volume (5.9\u00a0\u00b1\u00a01.2\u00a0L) decreased to 5.2\u00a0\u00b1\u00a01.1\u00a0L (\u201311%, P\u00a0=\u00a0.004) on low salt and low protein, and to 5.4\u00a0\u00b1\u00a00.9\u00a0L (\u20138%, P\u00a0=\u00a0.04) on low salt. Reduction in 24-h urine volume was two times greater in patients with lower urine osmolality (\u201316% vs \u20137%). Polyuria quality of life scores improved in concordance with changes in urine volume. mGFR decreased during the low salt and low protein, while mean arterial pressure did not change during study periods. Plasma copeptin decreased significantly during low salt and low protein periods.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Lowering dietary salt and protein intake has a minor effect on urine volume in V2RA-treated ADPKD patients. Reduced intake of osmoles decreased copeptin concentrations and might thus increase the renoprotective effect of a V2RA in ADPKD patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfad218","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T11:24:26Z","timestamp":1696677866000},"page":"707-716","source":"Crossref","is-referenced-by-count":5,"title":["Effects of salt and protein intake on polyuria in V2RA-treated ADPKD patients"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1376-9727","authenticated-orcid":false,"given":"Paul","family":"Geertsema","sequence":"first","affiliation":[{"name":"Departments of Nephrology, University Medical Center Groningen, University of Groningen , Groningen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris W","family":"Koorevaar","sequence":"additional","affiliation":[{"name":"Departments of Nephrology, University Medical Center Groningen, University of Groningen , Groningen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin J R","family":"Ipema","sequence":"additional","affiliation":[{"name":"Dietetics, University Medical Center Groningen, University of Groningen , Groningen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J","family":"Kramers","sequence":"additional","affiliation":[{"name":"Departments of Nephrology, University Medical Center Groningen, University of Groningen , Groningen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niek F","family":"Casteleijn","sequence":"additional","affiliation":[{"name":"Urology, University Medical Center Groningen, University of Groningen , Groningen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3223-0906","authenticated-orcid":false,"given":"Ron T","family":"Gansevoort","sequence":"additional","affiliation":[{"name":"Departments of Nephrology, University Medical Center Groningen, University of Groningen , Groningen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Meijer","sequence":"additional","affiliation":[{"name":"Departments of Nephrology, University Medical Center Groningen, University of Groningen , Groningen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,6]]},"reference":[{"key":"2024032707101185500_bib1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet North Am Ed"},{"key":"2024032707101185500_bib2","doi-asserted-by":"crossref","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","article-title":"Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival - an analysis of data from the ERA-EDTA Registry","volume":"29","author":"Spithoven","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2024032707101185500_bib3","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2215\/CJN.03960318","article-title":"Recent advances in the management of autosomal dominant polycystic kidney disease","volume":"13","author":"Chebib","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024032707101185500_bib4","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"2024032707101185500_bib5","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"2024032707101185500_bib6","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s40265-015-0475-x","article-title":"Tolvaptan: a review in autosomal dominant polycystic kidney disease","volume":"75","author":"Blair","year":"2015","journal-title":"Drugs"},{"key":"2024032707101185500_bib7","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1172\/JCI72272","article-title":"Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease","volume":"124","author":"Harris","year":"2014","journal-title":"J Clin Invest"},{"key":"2024032707101185500_bib8","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nrneph.2015.89","article-title":"Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus","volume":"11","author":"Bockenhauer","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"2024032707101185500_bib9","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/ajcn\/30.7.1070","article-title":"Role of diet in the management of vasopressin responsive and resistant diabetes insipidus","volume":"30","author":"Blalock","year":"1977","journal-title":"Am J Clin Nutr"},{"key":"2024032707101185500_bib10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.ajkd.2018.09.016","article-title":"Determinants of urine volume in ADPKD patients using the vasopressin V2 receptor antagonist tolvaptan","volume":"73","author":"Kramers","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2024032707101185500_bib11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/j.ajkd.2014.10.009","article-title":"Modifiable factors associated with copeptin concentration: a general population cohort","volume":"65","author":"Van Gastel","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2024032707101185500_bib12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of ADPKD","volume":"20","author":"Pei","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2024032707101185500_bib13","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.kint.2020.04.053","article-title":"Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease","volume":"98","author":"Kramers","year":"2020","journal-title":"Kidney Int"},{"key":"2024032707101185500_bib14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/ki.1985.10","article-title":"A method for estimating nitrogen intake of patients with chronic renal failure","volume":"27","author":"Maroni","year":"1985","journal-title":"Kidney Int"},{"key":"2024032707101185500_bib15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/00365517209084290","article-title":"A simple method for the determination of glomerular filtration rate","volume":"30","author":"Br\u00f6chner-Mortensen","year":"1972","journal-title":"Scand J Clin Lab Invest"},{"key":"2024032707101185500_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1681\/ASN.V62257","article-title":"Plasma clearance of nonradioactive lohexol as a measure of glomerular filtration rate","volume":"6","author":"Gaspari","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"2024032707101185500_bib17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1681\/ASN.V92310","article-title":"Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease","volume":"9","author":"Gaspari","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"2024032707101185500_bib18","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1088\/0967-3334\/30\/12\/006","article-title":"Accurate measurement of extracellular fluid volume from the slope\/intercept technique after bolus injection of a filtration marker","volume":"30","author":"Bird","year":"2009","journal-title":"Physiol Meas"},{"key":"2024032707101185500_bib19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1053\/j.ajkd.2017.08.020","article-title":"Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: a new health-related quality-of-life instrument","volume":"71","author":"Oberdhan","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2024032707101185500_bib20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s12020-015-0637-3","article-title":"Quality of life in the patients with central diabetes insipidus assessed by Nagasaki Diabetes Insipidus Questionnaire","volume":"51","author":"Nozaki","year":"2016","journal-title":"Endocrine"},{"key":"2024032707101185500_bib21","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1053\/j.ajkd.2014.11.010","article-title":"Short-term effects of tolvaptan in individuals with autosomal dominant polycystic kidney disease at various levels of kidney function","volume":"65","author":"Boertien","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2024032707101185500_bib22","article-title":"Clinical physiology of acid-base and electrolyte disorders, 5th edn","author":"Rose","year":"2001"},{"key":"2024032707101185500_bib23","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/jn\/106.5.665","article-title":"Protein requirements of man: obligatory urinary and fecal nitrogen losses in elderly women","volume":"106","author":"Scrimshaw","year":"1976","journal-title":"J Nutr"},{"key":"2024032707101185500_bib24","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.kint.2016.10.018","article-title":"Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease","volume":"91","author":"Torres","year":"2017","journal-title":"Kidney Int"},{"key":"2024032707101185500_bib25","doi-asserted-by":"crossref","first-page":"186","DOI":"10.7326\/0003-4819-144-3-200602070-00007","article-title":"Nephrogenic diabetes insipidus","volume":"144","author":"Sands","year":"2006","journal-title":"Ann Intern Med"},{"key":"2024032707101185500_bib26","first-page":"431","article-title":"Nephrogenic diabetes insipidus","volume":"105","author":"Bichet","year":"1998","journal-title":"Am Physiol Soc"},{"key":"2024032707101185500_bib27","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1476-5381.1992.tb09058.x","article-title":"Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist","volume":"105","author":"Yamamura","year":"1992","journal-title":"Br J Pharmacol"},{"key":"2024032707101185500_bib28","doi-asserted-by":"crossref","first-page":"e88409","DOI":"10.1172\/jci.insight.88409","article-title":"Metformin improves urine concentration in rodents with nephrogenic diabetes insipidus","volume":"1","author":"Efe","year":"2016","journal-title":"JCI Insight"},{"key":"2024032707101185500_bib29","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/jcph.880","article-title":"Pharmacokinetics and pharmacodynamics of tolvaptan in autosomal dominant polycystic kidney disease: phase 2 trials for dose selection in the pivotal phase 3 trial","volume":"57","author":"Shoaf","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2024032707101185500_bib30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.kint.2018.11.044","article-title":"Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease","volume":"96","author":"Gansevoort","year":"2019","journal-title":"Kidney Int"},{"key":"2024032707101185500_bib31","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-physiol-021113-170350","article-title":"Advances in understanding the urine-concentrating mechanism","volume":"76","author":"Sands","year":"2014","journal-title":"Annu Rev Physiol"},{"key":"2024032707101185500_bib32","first-page":"21","article-title":"Humoral factors involved in the regulation of sodium-fluid balance in normal man. I. Effect of dietary sodium chloride intake on renal prostaglandins, vasopressin and renin-angiotensin-aldosterone system","volume":"10","author":"Somova","year":"1984","journal-title":"Acta Physiol Pharmacol Bulg"},{"key":"2024032707101185500_bib33","first-page":"123","article-title":"Dietary sodium intake increases vasopressin secretion in man","volume":"1","author":"Kjeldsen","year":"1985","journal-title":"J Clin Hypertens"},{"key":"2024032707101185500_bib34","doi-asserted-by":"crossref","first-page":"F2","DOI":"10.1152\/ajprenal.00614.2014","article-title":"Protein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and urea","volume":"309","author":"Bankir","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"2024032707101185500_bib35","first-page":"350","article-title":"Effects of oral salt load on arginine-vasopressin secretion in normal subjects","volume":"17","author":"Spinelli","year":"1987","journal-title":"Ann Clin Lab Sci"},{"key":"2024032707101185500_bib36","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1210\/jc.2017-01891","article-title":"Release and decay kinetics of copeptin vs AVP in response to osmotic alterations in healthy volunteers","volume":"103","author":"Fenske","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2024032707101185500_bib37","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2024032707101185500_bib38","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","article-title":"KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2024032707101185500_bib39","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1681\/ASN.2016040448","article-title":"Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial","volume":"28","author":"Devuyst","year":"2017","journal-title":"J Am Soc Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfad218\/52581479\/gfad218.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/4\/707\/57094358\/gfad218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/4\/707\/57094358\/gfad218.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T08:08:53Z","timestamp":1711526933000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/39\/4\/707\/7296150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,10,6]]},"published-print":{"date-parts":[[2024,3,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfad218","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2023,10,6]]}}}